Publication | Closed Access
Treatment of malignant pheochromocytoma with a new radiopharmaceutical.
63
Citations
0
References
1983
Year
EngineeringMedicineTheranosticsPharmacologyPathologyRadiopharmaceutical TherapyMalignant PheochromocytomasPharmacotherapyAnti-cancer AgentAdrenal DiseaseMalignant PheochromocytomaComplex Molecular StructureOncologyRadiation OncologyNuclear MedicineObjective Responses
A new radiopharmaceutical, [131I]metaiodobenzylguandine, concentrates in some malignant pheochromocytomas. Five patients were treated with two to four doses of [131I]MIBG (99-197 mCi/dose). Two patients had substantial subjective and objective responses. [131I]MIBG is the first chemically synthesized radiopharmaceutical of complex molecular structure to reduce cancer.